Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYTK's Cash to Debt is ranked higher than
98% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CYTK: No Debt )
CYTK' s 10-Year Cash to Debt Range
Min: 2.9   Max: No Debt
Current: No Debt

Equity to Asset 0.80
CYTK's Equity to Asset is ranked higher than
82% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTK: 0.80 )
CYTK' s 10-Year Equity to Asset Range
Min: -1.73   Max: 0.96
Current: 0.8

-1.73
0.96
Interest Coverage No Debt
CYTK's Interest Coverage is ranked higher than
89% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTK: No Debt )
CYTK' s 10-Year Interest Coverage Range
Min: 63.8   Max: 9999.99
Current: No Debt

63.8
9999.99
F-Score: 3
Z-Score: -1.69
M-Score: 38.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -110.59
CYTK's Operating margin (%) is ranked higher than
69% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CYTK: -110.59 )
CYTK' s 10-Year Operating margin (%) Range
Min: -1961.56   Max: 32
Current: -110.59

-1961.56
32
Net-margin (%) -110.01
CYTK's Net-margin (%) is ranked higher than
68% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CYTK: -110.01 )
CYTK' s 10-Year Net-margin (%) Range
Min: -1912.57   Max: 30.1
Current: -110.01

-1912.57
30.1
ROE (%) -61.93
CYTK's ROE (%) is ranked higher than
59% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. CYTK: -61.93 )
CYTK' s 10-Year ROE (%) Range
Min: -113.28   Max: 24.2
Current: -61.93

-113.28
24.2
ROA (%) -40.53
CYTK's ROA (%) is ranked higher than
63% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CYTK: -40.53 )
CYTK' s 10-Year ROA (%) Range
Min: -90.69   Max: 20.02
Current: -40.53

-90.69
20.02
ROC (Joel Greenblatt) (%) -2775.92
CYTK's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. CYTK: -2775.92 )
CYTK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4057.87   Max: 702.8
Current: -2775.92

-4057.87
702.8
Revenue Growth (%) 67.10
CYTK's Revenue Growth (%) is ranked higher than
98% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CYTK: 67.10 )
CYTK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 154.8
Current: 67.1

0
154.8
EBITDA Growth (%) -34.80
CYTK's EBITDA Growth (%) is ranked higher than
57% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CYTK: -34.80 )
CYTK' s 10-Year EBITDA Growth (%) Range
Min: -53   Max: 2.5
Current: -34.8

-53
2.5
EPS Growth (%) -35.40
CYTK's EPS Growth (%) is ranked higher than
60% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CYTK: -35.40 )
CYTK' s 10-Year EPS Growth (%) Range
Min: -55   Max: 8.1
Current: -35.4

-55
8.1
» CYTK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CYTK Guru Trades in Q2 2013

Jim Simons Sold Out
» More
Q3 2013

CYTK Guru Trades in Q3 2013

Steven Cohen 15,403 sh (New)
» More
Q4 2013

CYTK Guru Trades in Q4 2013

Jim Simons 335,267 sh (New)
Steven Cohen Sold Out
» More
Q1 2014

CYTK Guru Trades in Q1 2014

Steven Cohen 700,500 sh (New)
Chuck Royce 700,000 sh (New)
Jim Simons 188,067 sh (-43.91%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2011-06-30 Sold Out $1.14 - $1.55 $ 4.34217%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.00
CYTK's P/B is ranked higher than
92% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. CYTK: 2.00 )
CYTK' s 10-Year P/B Range
Min: 0.89   Max: 6.94
Current: 2

0.89
6.94
P/S 3.60
CYTK's P/S is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. CYTK: 3.60 )
CYTK' s 10-Year P/S Range
Min: 1.39   Max: 97.81
Current: 3.6

1.39
97.81
EV-to-EBIT -2.59
CYTK's EV-to-EBIT is ranked higher than
66% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTK: -2.59 )
CYTK' s 10-Year EV-to-EBIT Range
Min: 2.1   Max: 7.1
Current: -2.59

2.1
7.1
Current Ratio 4.35
CYTK's Current Ratio is ranked higher than
74% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CYTK: 4.35 )
CYTK' s 10-Year Current Ratio Range
Min: 1.85   Max: 23.3
Current: 4.35

1.85
23.3
Quick Ratio 4.35
CYTK's Quick Ratio is ranked higher than
75% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CYTK: 4.35 )
CYTK' s 10-Year Quick Ratio Range
Min: 1.85   Max: 23.3
Current: 4.35

1.85
23.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.60
CYTK's Price/Net Cash is ranked higher than
96% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. CYTK: 2.60 )
CYTK' s 10-Year Price/Net Cash Range
Min: 0.99   Max: 9.18
Current: 2.6

0.99
9.18
Price/Net Current Asset Value 2.50
CYTK's Price/Net Current Asset Value is ranked higher than
96% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. CYTK: 2.50 )
CYTK' s 10-Year Price/Net Current Asset Value Range
Min: 0.99   Max: 8.36
Current: 2.5

0.99
8.36
Price/Tangible Book 1.80
CYTK's Price/Tangible Book is ranked higher than
94% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. CYTK: 1.80 )
CYTK' s 10-Year Price/Tangible Book Range
Min: 0.95   Max: 5.81
Current: 1.8

0.95
5.81
Price/Median PS Value 0.20
CYTK's Price/Median PS Value is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CYTK: 0.20 )
CYTK' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 4.79
Current: 0.2

0.11
4.79
Earnings Yield (Greenblatt) 6.20
CYTK's Earnings Yield (Greenblatt) is ranked higher than
75% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CYTK: 6.20 )
CYTK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.3   Max: 48.6
Current: 6.2

6.3
48.6
Forward Rate of Return (Yacktman) -59.88
CYTK's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. CYTK: -59.88 )
CYTK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -184   Max: -31.8
Current: -59.88

-184
-31.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:KK3A.Germany
Cytokinetics Inc was incorporated in Delaware in August 1997. Cytokinetics is a clinical-stage biopharmaceutical company engaged in discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its research and development activities relating to the biology of muscle function have evolved from its knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Its current research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The Company's cardiac muscle contractility program is focused on the cardiac sarcomere, the basic unit of muscle contraction in the heart. Its drug candidate from this program, omecamtiv mecarbil (formerly known as CK-1827452), is a novel cardiac muscle myosin activator. Amgen holds an exclusive license to develop and commercialize omecamtiv mecarbil worldwide, except Japan, subject to its development and commercialization participation rights. The Company is also conducting joint research with Amgen directed to next-generation compounds in its cardiac muscle contractility program. Tirasemtiv is the drug candidate from its skeletal sarcomere activator program. The Company has also conducted a Phase IIa clinical trial in patients with claudication, which is pain or cramping in the leg muscles due to inadequate blood flow during exercise, associated with peripheral artery disease. Tirasemtiv has received orphan drug designations from the FDA and the European Medicines Agency for the treatment of ALS. The Company is also advancing a structurally distinct, fast skeletal muscle sarcomere activator, CK-2127107, in non-clinical studies intended to enable the filing of an IND with the FDA. Its skeletal sarcomere activators selectively activate the fast skeletal muscle troponin complex, which is a set of regulatory proteins that modulates the contractility of the fast skeletal muscle sarcomere.. Two of its drug candidates directed to muscle contractility have now demonstrated pharmacodynamic activity in patients: omecamtiv mecarbil in patients with heart failure and tirasemtiv in patients with ALS and in patients with claudication associated with peripheral artery disease. The Company's competitors are ARCA biopharma, Inc., Nile Therapeutics, Inc., Ligand Pharmaceuticals, Inc., GTx, Inc., Acceleron Pharma, Inc., Biogen Idec, Inc., Mitsubishi Tanabe Pharma Corporation, Eisai Inc., Trophos SA, Neuraltus Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and GlaxoSmithKline plc. The Company's research, testing, manufacturing, selling and marketing of drugs are subject to extensive regulation by the FDA and other regulatory authorities in the United States.
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Aug 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares Jun 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares May 20 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares May 14 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) May 07 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 28 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 01 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 05 2009 
Cytokinetics Inc. (CYTK) President & CEO Robert I Blum sells 1,000 Shares Aug 06 2009 

More From Other Websites
Cytokinetics to Announce Second Quarter Results on July 30, 2014 Jul 16 2014
Cytokinetics to Announce Second Quarter Results on July 30, 2014 Jul 16 2014
Cytokinetics to Announce Second Quarter Results on July 30, 2014 Jul 16 2014
Cytokinetics Up on Positive Tirasemtiv Data Jul 14 2014
Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup... Jul 10 2014
Cytokinetics announces additional results relating to Tirasemtiv Jul 10 2014
CYTOKINETICS INC Files SEC form 8-K, Other Events Jul 10 2014
Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup... Jul 10 2014
Cytokinetics Announced Additional Results Relating to Tirasemtiv from Pre-Specificed Subgroup... Jul 10 2014
Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International... Jul 03 2014
Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International... Jul 03 2014
Cytokinetics Announces Additional Data from BENEFIT-ALS to be Presented at the 13th International... Jul 03 2014
CYTOKINETICS INC Files SEC form 8-K, Other Events Jun 13 2014
Cytokinetics Announces Data Relating to Tirasemtiv Presented at the 2014 Annual Spinal Muscular... Jun 13 2014
Cytokinetics Announces Data Relating to Tirasemtiv Presented at the 2014 Annual Spinal Muscular... Jun 13 2014
Cytokinetics Announces Two Presentations Relating to Tirasemtiv to be Presented at the 2014 Annual... Jun 06 2014
Cytokinetics Announces Two Presentations Relating to Tirasemtiv to be Presented at the 2014 Annual... Jun 06 2014
CYTOKINETICS INC Files SEC form 8-K, Other Events Jun 02 2014
Cytokinetics Announces Further Results from BENEFIT-ALS Relating to Effects Following Withdrawal of... Jun 02 2014
Cytokinetics Announces Further Results from BENEFIT-ALS Relating to Effects Following Withdrawal of... Jun 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide